Evidence supporting the use of: N-Acetyl Cysteine
For the health condition: Chronic Obstructive Pulmonary Disorder

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

N-Acetyl Cysteine (NAC) is primarily used in Chronic Obstructive Pulmonary Disease (COPD) due to its mucolytic and antioxidant properties. NAC acts as a precursor to glutathione, a major endogenous antioxidant, and helps to reduce oxidative stress in the lungs, which is a key component of COPD pathology. Several randomized controlled trials and meta-analyses have investigated its efficacy. The evidence suggests that regular oral administration of NAC (typically 600-1200 mg daily) can reduce the frequency of exacerbations in patients with moderate to severe COPD, particularly those not already taking inhaled corticosteroids. However, the effect size is modest, and not all studies have shown significant improvements in lung function or quality of life. Guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) note that while NAC may be considered in select patients, especially in regions where it is commonly used, its overall benefit is limited. Nevertheless, the use of NAC in COPD is supported by a moderate level of clinical evidence and is included in some treatment protocols, particularly in Europe and Asia. It is not a first-line therapy but may be considered as an adjunct in patients with frequent exacerbations despite optimal standard treatment.

More about N-Acetyl Cysteine
More about Chronic Obstructive Pulmonary Disorder

Products containing N-Acetyl Cysteine

We currently have no products on Vitabase that contain this ingredient.